Literature DB >> 12197893

T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking.

P Kivisäkk1, C Trebst, Z Liu, B H Tucky, T L Sørensen, R A Rudick, M Mack, R M Ransohoff.   

Abstract

It is believed that chemokines and their receptors are involved in trafficking of T-cells to the central nervous system (CNS). The aim of the current study was to define the expression on cerebrospinal fluid (CSF) T-cells of six chemokine receptors associated with trafficking to sites of inflammation. Flow cytometry was used to detect chemokine receptor expression. We observed that CD3+T-cells in the CSF express a restricted array of inflammatory chemokine receptors, specifically CXCR3, CCR5 and CCR6, but little CCR1-3. This repertoire was independent of the presence of CNS inflammation, since comparable findings were obtained in patients with multiple sclerosis (MS) and individuals with non-inflammatory neurological diseases. The enrichment of CCR5+T-cells in the CSF could largely be explained by higher frequency of CD4+/CD45RO+T-cells in this compartment. In contrast, CD4+/CD45RO+T-cells expressing CXCR3 were significantly enriched in CSF as compared with blood. Similar levels of CCR6+/CD3+T-cells were observed in blood and CSF, while levels of CCR2+/CD3+T-cells were lower in CSF than in blood. The CSF was virtually devoid of CCR5+/CXCR3- T-cells, suggesting that the expression of CCR5 alone is not sufficient for the trafficking of CD3+T-cells to the CSF. We hypothesize that CXCR3 is the principal inflammatory chemokine receptor involved in intrathecal accumulation of T-cells in MS. Through interactions with its ligands, CXCR3 is proposed to mediate retention of T-cells in the inflamed CNS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12197893      PMCID: PMC1906480          DOI: 10.1046/j.1365-2249.2002.01947.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  56 in total

Review 1.  International union of pharmacology. XXII. Nomenclature for chemokine receptors.

Authors:  P M Murphy; M Baggiolini; I F Charo; C A Hébert; R Horuk; K Matsushima; L H Miller; J J Oppenheim; C A Power
Journal:  Pharmacol Rev       Date:  2000-03       Impact factor: 25.468

Review 2.  Chemokines: a new classification system and their role in immunity.

Authors:  A Zlotnik; O Yoshie
Journal:  Immunity       Date:  2000-02       Impact factor: 31.745

Review 3.  Chemokines in tissue-specific and microenvironment-specific lymphocyte homing.

Authors:  J J Campbell; E C Butcher
Journal:  Curr Opin Immunol       Date:  2000-06       Impact factor: 7.486

4.  CCR2 expression determines T1 versus T2 polarization during pulmonary Cryptococcus neoformans infection.

Authors:  T R Traynor; W A Kuziel; G B Toews; G B Huffnagle
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

5.  Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment.

Authors:  M D Carrithers; I Visintin; S J Kang; C A Janeway
Journal:  Brain       Date:  2000-06       Impact factor: 13.501

6.  Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver.

Authors:  P L Shields; C M Morland; M Salmon; S Qin; S G Hubscher; D H Adams
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

7.  Expression and coreceptor activity of STRL33/Bonzo on primary peripheral blood lymphocytes.

Authors:  M Sharron; S Pöhlmann; K Price; E Lolis; M Tsang; F Kirchhoff; R W Doms; B Lee
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

8.  Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions.

Authors:  J E Simpson; J Newcombe; M L Cuzner; M N Woodroofe
Journal:  Neuropathol Appl Neurobiol       Date:  2000-04       Impact factor: 8.090

9.  Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients.

Authors:  T L Sørensen; M Tani; J Jensen; V Pierce; C Lucchinetti; V A Folcik; S Qin; J Rottman; F Sellebjerg; R M Strieter; J L Frederiksen; R M Ransohoff
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

10.  CC-chemokine receptor 6 is expressed on diverse memory subsets of T cells and determines responsiveness to macrophage inflammatory protein 3 alpha.

Authors:  F Liao; R L Rabin; C S Smith; G Sharma; T B Nutman; J M Farber
Journal:  J Immunol       Date:  1999-01-01       Impact factor: 5.422

View more
  48 in total

1.  Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals.

Authors:  Pia Kivisäkk; Corinna Trebst; Jar-Chi Lee; Barbara H Tucky; Richard A Rudick; James J Campbell; Richard M Ransohoff
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

Review 2.  [Chemokine--possible new options for the treatment of multiple sclerosis].

Authors:  C Trebst; R M Ransohoff; A Windhagen; M Stangel
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

Review 3.  Trafficking of immune cells in the central nervous system.

Authors:  Emma H Wilson; Wolfgang Weninger; Christopher A Hunter
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

4.  Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control.

Authors:  N Schwab; J C Ulzheimer; R J Fox; T Schneider-Hohendorf; B C Kieseier; C M Monoranu; S M Staugaitis; W Welch; S Jilek; R A Du Pasquier; W Brück; K V Toyka; R M Ransohoff; H Wiendl
Journal:  Neurology       Date:  2012-02-01       Impact factor: 9.910

5.  Differences in systemic and central nervous system cellular immunity relevant to relapsing-remitting multiple sclerosis.

Authors:  Makoto Matsui; Shin-ichi Araya; Hui-Yun Wang; Kouji Matsushima; Takahiko Saida
Journal:  J Neurol       Date:  2005-03-21       Impact factor: 4.849

6.  Longitudinal analysis of activation markers on monocyte subsets during the development of simian immunodeficiency virus encephalitis.

Authors:  Stephanie J Bissel; Guoji Wang; Anita M Trichel; Michael Murphey-Corb; Clayton A Wiley
Journal:  J Neuroimmunol       Date:  2006-06-21       Impact factor: 3.478

7.  Immune-cell crosstalk in multiple sclerosis.

Authors:  Richard M Ransohoff
Journal:  Nature       Date:  2018-11       Impact factor: 49.962

8.  SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients.

Authors:  George P Christophi; Chad A Hudson; Ross C Gruber; Christoforos P Christophi; Cornelia Mihai; Luis J Mejico; Burk Jubelt; Paul T Massa
Journal:  Lab Invest       Date:  2008-01-21       Impact factor: 5.662

9.  Pro-inflammatory functions of astrocytes correlate with viral clearance and strain-dependent protection from TMEV-induced demyelinating disease.

Authors:  Pamela A Carpentier; Meghann Teague Getts; Stephen D Miller
Journal:  Virology       Date:  2008-03-04       Impact factor: 3.616

10.  Increased Intrathecal Chemokine Receptor CCR2 Expression in Multiple Sclerosis.

Authors:  Hideto Nakajima; Masakazu Sugino; Fumiharu Kimura; Toshiaki Hanafusa; Toshiyuki Ikemoto; Akira Shimizu
Journal:  Biomark Insights       Date:  2007-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.